Vestal Point Capital, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001974915

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2025 · 81 positions · Total reported value $2.21B · Top-10 concentration 38.3% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 64.6% · 14 new · 20 cut · 19 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.4% · vs SPY -15.5% · Prev Value $4.28B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -2.9% · vs SPY -5.1% · Latest Value $3.87B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2025 13F filing, Vestal Point Capital, LP disclosed 81 equity positions with a combined reported value of $2.21B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 38.3% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2025 were ASND ($119.29M), ACLX ($102.62M), NUVL ($95.13M). By sector, the heaviest allocations are Health Care 78.0%, Industrials 2.0%. Versus the prior quarter, allocation shifted toward Health Care (+8.5pp) and away from Other (-8.4pp).

Versus the prior quarter, Vestal Point Capital, LP opened 14 new positions, trimmed 20 and fully exited 19, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 61% of names.

The largest new positions opened in Q3 2025 were ABVX ($84.90M), RGEN ($53.47M), DXCM ($43.74M).

Of the 19 positions fully exited versus the prior quarter, the largest were GEHC ($51.85M), MLTX ($25.96M), COO ($24.91M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2025)

  • ABVX ABIVAX SA · $84.90M
  • RGEN REPLIGEN CORP · $53.47M
  • DXCM DEXCOM INC · $43.74M
  • BIIB BIOGEN INC · $38.52M
  • RAPP RAPPORT THERAPEUTICS INC · $28.21M
  • BLTE BELITE BIO INC · $23.12M
  • RARE ULTRAGENYX PHARMACEUTICAL IN · $22.56M
  • AXSM AXSOME THERAPEUTICS INC. · $18.22M

Fully Exited (vs previous quarter)

  • GEHC GE HEALTHCARE TECHNOLOGIES I · prev qtr: $51.85M
  • MLTX MOONLAKE IMMUNOTHERAPEUTICS · prev qtr: $25.96M · history
  • COO COOPER COS INC · prev qtr: $24.91M
  • GPCR STRUCTURE THERAPEUTICS INC · prev qtr: $24.89M
  • EW EDWARDS LIFESCIENCES CORP · prev qtr: $23.46M
  • COGT COGENT BIOSCIENCES INC · prev qtr: $22.11M · history
  • MDT MEDTRONIC PLC · prev qtr: $17.00M
  • PRGO PERRIGO CO PLC · prev qtr: $16.70M

Insider Transactions (Form 4)

Latest Vestal Point Capital, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Vestal Point Capital, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 63 US equity positions with a combined value of $3.87B. HoldingsHub carries 12 quarters of its filings (Q4 2023–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-127682 (status: Approved), registered 2023-04-14
  • Regulatory AUM (Form ADV): $5.47B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds
  • Website: vestalpoint.com

Portfolio Structure

  • 63 positions · $3.87B reported value (Q3 2026)
  • Top 10 holdings = 67.3% of reported value
  • Largest position: ABVX (ABIVAX SA) at 10.1%
  • Average position size: $61.44M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 14 new, 22 added, 20 reduced, 19 exited
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 78.0%
Other 20.1%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 600.00K $119.29M 5.39%
5.39%
Add
2 1.25M $102.62M 4.63%
4.63%
Reduce
3 1.10M $95.13M 4.30%
4.30%
Add
4 1.00M $84.90M 3.83%
3.83%
New
5 1.10M $81.96M 3.70%
3.70%
Add
6 5.10M $80.53M 3.64%
3.64%
Add
7 9.75M $76.83M 3.47%
3.47%
Reduce
8 1.25M $71.59M 3.23%
3.23%
Add
9 1.07M $70.33M 3.18%
3.18%
Add
10 500.00K $65.90M 2.98%
2.98%
Reduce
11 325.00K $60.83M 2.75%
2.75%
Add
12 1.50M $55.86M 2.52%
2.52%
Hold
13 6.35M $54.10M 2.44%
2.44%
Add
14 400.00K $53.47M 2.42%
2.42%
New
15 1.18M $46.43M 2.10%
2.10%
Reduce
16 830.00K $44.95M 2.03%
2.03%
Add
17 1.10M $44.16M 1.99%
1.99%
Reduce
18 650.00K $43.74M 1.98%
1.98%
New
19 725.00K $39.85M 1.80%
1.80%
Reduce
20 275.00K $38.52M 1.74%
1.74%
New
21 400.00K $38.30M 1.73%
1.73%
Reduce
22 4.96M $36.08M 1.63%
1.63%
Add
23 2.77M $35.10M 1.58%
1.58%
Add
24 2.42M $33.93M 1.53%
1.53%
Reduce
25 250.00K $33.48M 1.51%
1.51%
Add
26 500.00K $33.04M 1.49%
1.49%
Add
27 3.48M $32.11M 1.45%
1.45%
Add
28 750.00K $31.24M 1.41%
1.41%
Reduce
29 1.21M $31.17M 1.41%
1.41%
Reduce
30 1.76M $30.15M 1.36%
1.36%
Add
31 150.00K $29.74M 1.34%
1.34%
Add
32 630.00K $29.42M 1.33%
1.33%
Reduce
33 950.00K $28.21M 1.27%
1.27%
New
34 1.16M $23.75M 1.07%
1.07%
Add
35 17.23M $23.60M 1.07%
1.07%
Reduce
36 312.50K $23.12M 1.04%
1.04%
New
37 750.00K $22.56M 1.02%
1.02%
New
38 760.00K $22.09M 1.00%
1.00%
Reduce
39 3.25M $21.58M 0.97%
0.97%
Add
40 5.55M $21.03M 0.95%
0.95%
Reduce
41 2.67M $18.86M 0.85%
0.85%
Reduce
42 2.98M $18.36M 0.83%
0.83%
Add
43 150.00K $18.22M 0.82%
0.82%
New
44 5.50M $17.98M 0.81%
0.81%
Add
45 425.00K $16.89M 0.76%
0.76%
New
46 4.01M $14.33M 0.65%
0.65%
Reduce
47 440.00K $14.30M 0.65%
0.65%
Reduce
48 25.00K $14.06M 0.64%
0.64%
New
49 225.00K $13.13M 0.59%
0.59%
Reduce
50 600.00K $11.92M 0.54%
0.54%
Add

FAQ

What did Vestal Point Capital, LP buy in 2025-Q3?

In its 2025-Q3 13F filing, Vestal Point Capital, LP reported 81 equity positions worth $2.21B in aggregate; its largest disclosed positions were ASND ($119.29M), ACLX ($102.62M), NUVL ($95.13M).

How large is Vestal Point Capital, LP's portfolio?

Vestal Point Capital, LP reported $2.21B of long equity holdings across 81 positions as of 2025-Q3. Top-10 holdings account for 38.3% of reported value.

What is Vestal Point Capital, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/vestal-point-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →